Transforming fragmented evidence into clear decisions.
Hubert Rose Consulting helps biotech companies cut through fragmented evidence and reach clear strategic decisions. With more than two decades of industry experience, the firm provides expert guidance across development and commercialization.
Hubert Rose Consulting
We provide strategy and advisory services
- Evidence-to-Decision Assessments
- Evidence Roadmaps
- Value Story / Evidence Narratives
- Data Assessment Plans
- HEOR Research Plans
Additional Services
- Competitive Evidence Benchmarking
- Due Diligence Evidence Appraisals
- Data-to-Decision Advisory Retainers
Deliverable Previews
We turn fragmented evidence into decision-ready recommendations.
Our methodology combines structured evidence review, stakeholder mapping, and lifecycle prioritization to identify evidence strengths and gaps. Every recommendation stems from the evidence you have, clearly flagging where the evidence is still incomplete.
Read the methodology →Stakeholders assessed
Geographies & HTA regimes
Lifecycle coverage
Phase II → Phase III → Pre-Launch → Lifecycle Management.
The E2D Toolkit is our proprietary review framework.
Judgment gated
Nothing is auto-accepted. Every output from the E2D toolkit is confirmed or dismissed by a senior expert.
Stakeholder aware
Evidence is judged against stakeholder need, decision timing, and asset context.
Always learning
The E2D Toolkit is updated as evidence standards, stakeholder expectations, and market access requirements evolve.
Bring your evidence. We'll bring the clarity.
Message us on LinkedIn or start a conversation here if your team is approaching a decision where the inputs exist, but the path forward is not yet clear.
Start an engagement